hypertrophy and survival) has not been established. The present study was designed to evaluate the impact of low-dose ACE inhibition (predominant inhibition of plasma ACE) and high-dose ACE inhibition (associated with substantial tissue ACE inhibition) on reversal of LV hypertrophy and 1-year mortality after myocardial infarction in the rat.
Methods and Results Infarcted rats were randomized to placebo, low-dose lisinopril, or high-dose lisinopril (each, n=80) and compared with sham-operated animals (n=40). In a separate group of animals, tissue ACE activity was determined after 6 weeks of therapy, demonstrating that both regimens were effective with regard to both plasma and T he rat model of chronic myocardial infarction (MI) induced by coronary artery ligation represents a well-characterized animal model of chronic congestive heart failure. MI in the rat model results in a profound alteration of ventricular architecture characterized by early expansion of the infarcted area,' ventricular dilatation,2 and hypertrophy of the noninfarcted left ventricle (LV).3 This cardiac remodeling process can be attenuated by long-term treatment with the hemodynamically effective angiotensin-converting enzyme (ACE) inhibitor captopril,4 resulting in improved long-term survival. 5 On the basis of this beneficial effect of captopril in the rat infarct model, clinical trials have now provided convincing evidence that this therapeutic principle also applies for patients with large MI. 6 Since the plasma renin-angiotensin system (RAS) is not consistently activated after MI,7.8 the beneficial effects of ACE inhibition have been attributed, in part, to inhibition of an activated tissue RAS. Indeed, recent studies strongly suggest a selective activation of the tissue RAS in the heart and in the kidneys after MI in the rat, which could represent a target for ACE inhibitors.9"10 Evidence is accumulating that the cardiac RAS is involved in the stretch-mediated hypertrophic response of cardiac myocytes.1"-3 Conceivably, interfering with the activated cardiac RAS may prevent the development of LV remodeling and hypertrophy after MI. However, data demonstrating a relation between the degree of cardiac tissue ACE inhibition and the effect of ACE inhibitors on LV hypertrophy and survival are lacking. Alternatively, the beneficial effects of long-term ACE inhibition on survival after MI may be predominantly due to systemic effects and inhibition of renal tissue ACE, thereby reducing preload and afterload.
In the clinical setting, ACE inhibitors are often prescribed in very low doses, assuming that low doses may be as effective and have fewer side effects compared with the recommended dose.14 Indeed, experimental data obtained from a high renin-pressure overload model suggested that ACE inhibitors can prevent LV hypertrophy in nonhypotensive doses. '5 To the contrary, most clinical trials have used high target doses of ACE inhibitors for the treatment of chronic heart failure.616"7 Accordingly, the present study was designed to evaluate the impact of low-dose ACE inhibition (predominant inhibition of plasma RAS) and highdose ACE inhibition (associated with substantial tissue ACE inhibition) on reversal of LV hypertrophy and 1-year mortality after MI in the rat. Methods
Experimental Infarction
Male Sprague-Dawley rats weighing 250 to 300 g were obtained from the Zentralinstitut fur Versuchstierkunde, Hannover, FRG, and housed in our animal facility for at least 4 days before operation. The animal studies were approved by the Ethical Committee for Animal Research at the University of Freiburg, FRG. Coronary artery ligation was performed as previously described.1819 Briefly, rats were anesthetized with pentobarbital and ketamine. The left coronary artery was ligated approximately 2 mm distal to its aortic origin with a 6.0 Prolene suture. There was an '40% mortality rate within the first 48 hours. In sham-operated animals, the suture was tied loosely so as not to obstruct coronary flow. Animals were allowed free access to a 0.5% sodium standard rat chow. Drinking water was provided ad libitum.
Administration of Lisinopril
The ACE inhibitor lisinopril was dissolved in the drinking water at concentrations of 3.85 mg/L (low dose) and 38.5 mg/L (high dose). The dose selection was based on a pilot study demonstrating that these dosages result in serum lisinopril levels comparable to a low dose of approximately 2.5 to 5 mg/d or a high dose of approximately 20 mg/d.20, 21 The high dose was equivalent to the target dose in large clinical trials.1416 The pilot study also documented an effective inhibition of plasma ACE activity and a significant rightward shift of the angiotensin (Ang) I pressure-response curve during both low-and high-dose treatment.
Instrumentation
Rats were anesthetized with halothane (1% in oxygen). Saline-filled catheters (PE 50) were inserted into the right carotid artery and jugular vein. The arterial line was connected to a Statham P231D pressure transducer. Blood pressure tracings were displayed on a recorder screen (Elema Mingograph, Siemens). After closure, rats were allowed to recover for a minimum of 3 hours before hemodynamic measurements were performed. This recovery period is of sufficient duration to ensure a return to baseline conditions in the rat. 22 
Angiotensin Challenges
To document effective and sustained plasma ACE inhibition (particularly during low-dose lisinopril therapy), Ang I and Ang II dose-response curves were obtained at 2 weeks and 1 year of therapy. Baseline arterial blood pressure and heart rate were recorded. Subsequently, pressure responses to Ang I and Ang II (Sigma) were determined. Increasing doses of Ang I and Ang 11 (1, 3, 10, 30 , 100, 300, and 1000 ng) were injected intravenously in 0.1 mL saline. A 5-minute interval was maintained between pressure stimuli. The angiotensin dosages were increased until a 20 mm Hg peak change in mean arterial blood pressure was observed. Dose-response curves for Ang I and Ang II were derived from the peak changes in mean arterial pressure.
Determination of Infarct Size
The LV was fixed in 10% formalin and embedded in paraffin. Six transverse slices were cut from apex to base. A 5-,um section was cut from each slice and mounted. The sections were stained with sirius red (0.1% solution in saturated aqueous picric acid) to provide a clear discrimination between fibrous scar and noninfarcted tissue.23 Infarct size was determined by planimetric measurement4 with a digital image analyzer (Leitz). To calculate infarct size, the ratios of scar length to circumference from each of the six slices were averaged and expressed as percentage.
Tissue Sampling
Rats were killed in the early morning by decapitation. Trunk blood was collected into chilled tubes containing either heparin (200 IU/mL) or EDTA disodium salt (1 mg/mL). The tubes were immediately centrifuged at 4°C. Plasma containing heparin was snap-frozen and stored in liquid nitrogen until assay of ACE activity. Plasma containing EDTA was divided into two samples. The first sample was stored at -80°C for later determination of plasma renin activity. Aprotinin (500 KIU/mL plasma, Bayer) was added to the second sample, which was then stored in liquid nitrogen for later assay of atrial natriuretic peptide (ANF). The thoracic contents were removed en bloc. Major pulmonary trunks were removed from the lungs. The atria and the right ventricle were dissected from the LV. The infarct scar and the border zone were separated from viable LV myocardium. In sham-operated animals, corresponding parts of the LV were discarded. Only viable LV myocardium (representing the inferior wall and the interventricular septum) was used for the subsequent analyses. The kidneys were freed of their capsules. All tissues were rinsed in ice-cold saline, blotted dry, weighed, and snap-frozen. Tissues were either stored in liquid nitrogen for subsequent assay of ACE activity or stored at -80°C for later isolation of RNA.
Biochemical Measurements
Serum lisinopril concentration was determined by radioimmunoassay.24 Plasma renin activity was measured by radioimmunoassay of Ang I generated by incubation with an excess of rat renin substrate. 25 3 mmol/L MgC12), 0.5 mmol/L dNTPs (Pharmacia), and 250 pmol of random hexanucleotide primers. The mixtures were heated at 72°C for 3 minutes followed by cooling to 42°C.
Subsequently, dithiothreitol (final concentration, 10 mmol/L), RNase inhibitor (2 U/100 ng of total RNA, Life Technologies), and Moloney murine leukemia virus reverse transcriptase (10 U/100 ng of total RNA, Life Technologies) were added, and the reaction mixtures were incubated at 42°C for 60 minutes. As a negative control, one additional reaction mixture was set up omitting the reverse transcriptase.
PCR Amplification
Duplicate samples of PCR reaction were performed in a total volume of 50 ,L, respectively, each containing 10 uL of reverse transcription reaction, 35 Ten microliters from each PCR reaction was loaded onto 1.5% agarose gels containing 0.5 ,g/mL ethidium bromide. After electrophoresis, the amplification products of the template and the competitor were visualized by UV illumination, and a photograph was taken. The negative films were used to evaluate the band intensities by laser densitometry (Personal Densitometer). To correct for the difference in molecular weight, the band densities of the ACE competitor product were multiplied by 1.56 (881 bp divided by 566 bp). The ratios of the corrected band densities of the competitor products to the band densities of the template products were calculated, and the logarithmic values were plotted against the logarithm of the known number of competitor cRNA molecules. At the point at which the products of the competitor cRNA and the template RNA are in equivalence (log ratio=0), the starting concentration of the template RNA equals the starting concentration of the competitor RNA. The linearity of the competitive RT-PCR was verified by subjecting five dilutions of LV RNA (0, 0.313, 0.625, 1.25, and 1.875 ,ug) to reverse transcription and subsequent PCR amplification. This resulted in a linear relationship (r=.99, P<.001). The competitive RT-PCR was reproducible with repetitive measurements from individual samples differing <15% from each other.
Protocol 1
Six to 8 days after coronary artery ligation, rats were randomly assigned to vehicle (MI-V) or low-dose (MI-L) or high-dose lisinopril (MI-H, n=7 to 10 per group). After treatment for 14 days, catheters were inserted into the right carotid artery and jugular vein. A 0.4-mL venous blood sample was withdrawn for determination of serum lisinopril concentration. After recovery (>3 hours), baseline arterial blood pressure and heart rate were measured in resting conscious rats. Subsequently, blood pressure response curves to intravenous Ang I and Ang II were recorded. At the end of the protocol, the hearts were removed under halothane anesthesia and placed in 10% formalin for later determination of infarct size. The same protocol was carried out after treatment for 1 year using animals that completed protocol 3 (n=6 to 8 per group).
Protocol 2
Six to 8 days after coronary artery ligation, rats were randomized to receive vehicle (MI-V, n= 16) 
Results
Protocol 1 The effects of low-dose and high-dose lisinopril on resting arterial blood pressure, heart rate, and pressure responses to Ang I and Ang II were determined in two separate sets of animals after treatment for 2 weeks or for 1 year, respectively (Table 1, Fig 2) . There were no significant differences in infarct size between the treatment groups. Plasma lisinopril concentrations were significantly higher in high-dose compared with low-dose treatment (P<.05, Table 2 . Compared with sham-operated animals, the ACE activity in the noninfarcted parts of the LV significantly increased in infarcted animals receiving vehicle (P<.05), whereas the ACE activities in the lungs, in the kidney, and in plasma did not differ significantly between these two groups. Plasma and pulmonary ACE activities were significantly inhibited by high-dose and by low-dose lisinopril treatment (P<.001). A significant inhibition of renal ACE activity was achieved only by high-dose lisinopril (P<.001 versus placebo and P<.05 versus low-dose lisinopril). The ACE activity in the noninfarcted parts of the LV remained unchanged during low-dose and high-dose lisinopril treatment.
Chronic MI was associated with a significant elevation of plasma ANF levels (P<.01) ( Table 3) . ANF levels tended to decrease with lisinopril treatment. Plasma renin activity in vehicle-treated infarcted and shamoperated rats did not differ significantly. An increase in plasma renin activity was observed during low-dose and high-dose lisinopril treatment (P<.001, Table 3 ).
By use of competitive RT-PCR, ACE mRNA levels were measured in the noninfarcted parts of the LV. As shown in Fig 3, the number of ACE transcripts per 500 ng total RNA significantly increased in vehicle-treated infarcted rats compared with sham-operated rats (4.7±0.5 x 106 versus 2.6±0.3 x 106, P< .02). Infarcted animals treated with low doses or high doses of lisinopril did not differ from vehicle-treated infarcted animals with regard to LV ACE mRNA expression. There was a significant positive correlation between LV ACE mRNA expression and ACE activity (n=21, r=.57, P=.007, Fig 4) . . Based on the planimetric determination of infarct size, rats were classified as having small (<20%), moderate (>20%, <40%), or large (>40%) infarcts. Infarct sizes did not differ significantly within these three groups. High-dose lisinopril caused a significant reduction in the 1-year mortality rate of rats with small and moderate infarcts. Although there were no significant differences in survival for large infarcts, the number of animals in each treatment group was too small to allow definite conclusions. Low-dose treatment did not prove to be effective in any of the three groups (Table 4 ). In all animals of protocol 3, body weights and ventricular weights were determined after death or after 1 year (Table 5) . Compared with sham-operated rats, the relative LV weight and the absolute and relative right ventricular weights were increased in placebo-treated infarcted rats. High-dose treatment resulted in a significant reduction of ventricular weights compared with placebo and low-dose treatment. Since more rats of the placebo and low-dose infarct groups died before the end of the 1-year treatment period compared with the high-dose group, the development of higher cardiac weights in the placebo and low-dose groups is likely to underestimate the extent of cardiac hypertrophy that might have emerged if these animals had lived longer. 
Discussion
The present study provides the first evidence that the effect of long-term ACE inhibition on survival after MI is dose-dependent. Low doses of an ACE inhibitor, although exerting effective inhibition of the plasma RAS, may not improve survival. In contrast, high doses (equivalent to doses used in clinical trials), associated with renal tissue ACE inhibition, sustained reduction of blood pressure, and prevention of LV hypertrophy, result in a dramatic decrease of long-term mortality in the rat model.
Influence of Low-Dose and High-Dose Lisinopril on Long-term Mortality
The beneficial effects of chronic ACE inhibition on long-term survival after MI were first demonstrated in the rat infarct model. 5 The results of this animal study provided the basis for the design of the subsequent clinical trials,6 which, in turn, confirmed the experimental findings demonstrating that ACE inhibitors reduce mortality in patients after MI. Thus, this animal model has proved to be extremely useful for studying pharmacological aspects of LV dysfunction after MI. The impressive results of the clinical trials have been obtained with fairly high target doses of ACE inhibitors, ie, 100 to 150 mg captopril.6 On the assumption that low doses might be as effective as high doses while reducing side effects, low doses are commonly used in clinical practice,14 although the optimal dose regimen for improvement of survival remains to be defined and may differ from doses that alleviate symptoms.
In the present study, we used the rat model of chronic MI to compare two dosages of lisinopril that resulted in serum drug concentrations comparable to the drug levels seen in heart failure patients receiving a low dose of~2.5 to 5 mg/d or a high dose of :20 mg/d.2021 The latter dose is equivalent to the target dose of enalapril used in large clinical trials.6'1617 Treatment with the high dose resulted in a substantial reduction of the 1-year mortality rate, whereas the low dose did not. Importantly, the 1-year mortality rate of rats receiving highdose lisinopril was significantly lower than the mortality rate of rats on low-dose treatment. In an additional analysis, the mortality data were stratified according to infarct size and analyzed with a Cox proportionalhazards model. In relation to the 1-year mortality of vehicle-treated infarcted rats, low-dose treatment caused a nonsignificant 19.9% risk reduction, whereas high-dose treatment resulted in a highly significant risk reduction of 71.1%. To analyze whether the effects of low-dose or high-dose lisinopril depend on infarct size, rats were classified as having small, moderate, and large infarcts. Low-dose treatment did not reduce long-term mortality in any of the three groups, whereas the high dose prolonged survival in rats with small and moderate infarcts. These findings are consistent with earlier results of Pfeffer et al,5 who demonstrated that a hypotensive dose of captopril reduced the long-term mortality of rats with moderate but not with large infarcts. Plasma and Tissue ACE Activities During Chronic Lisinopril Treatment
What are the mechanisms that underlie the therapeutic efficacy of the "high" dose, and why did the "low" dose fail to reduce long-term mortality? The analysis of the data of the 1-year treatment protocol as well as in rats treated for 6 weeks (ie, before the onset of excess mortality in the infarcted animals). This suggests that the high-dose regimen prevented the development of reactive hypertrophy of the LV. Conversely, the LV weights of placebo-and low-dosetreated infarcted rats were similar compared with sham animals, indicating the presence of reactive cardiac hypertrophy compensating for the loss of myocardium after infarction, which is replaced by scar tissue of low mass density. Thus, improved survival after MI achieved by high-dose treatment was associated with prevention of LV hypertrophy, and the failure of lowdose lisinopril to improve survival was associated with development of LV hypertrophy. Although the association does not prove a causal relation, it is tempting to speculate that reduction in LV hypertrophy during ACE inhibitor therapy is a marker for a beneficial effect on survival. Our 
